<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749526</url>
  </required_header>
  <id_info>
    <org_study_id>JS-ENDO-003</org_study_id>
    <nct_id>NCT02749526</nct_id>
  </id_info>
  <brief_title>Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endostar ® (recombinant human endostatin) continuous intravenous infusion combined with mPFC&#xD;
      neoadjuvant treatment of esophageal cancer arm, Ⅱ single-center clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Research purpose: Endostar (recombinant human endostatin) continuous intravenous&#xD;
           infusion combined with chemotherapy for stage Ⅲ resectable or potentially resectable&#xD;
           esophageal cancer efficacy and safety and to maintain the efficacy and safety.&#xD;
&#xD;
        2. The main objectives: R0 resection rate&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. pCR rate&#xD;
&#xD;
        2. 3-year disease-free survival&#xD;
&#xD;
        3. Security and complications&#xD;
&#xD;
        4. DFS, OS&#xD;
&#xD;
        5. Quality of Life&#xD;
&#xD;
      3.The number of research centers and research time: This study intends to preside and&#xD;
      implemented by the Jiangsu Provincial People's Hospital, Professor Gu Yanhong. The trial is&#xD;
      scheduled to start in September 2015, planned to stop in June 2016 into the group, one&#xD;
      patient surgery follow-up to the last end, get the primary endpoint and safety, surgical&#xD;
      complications secondary endpoint. This study will continue to follow-up the patient DFS, OS&#xD;
      and other secondary end points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual rate&#xD;
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 Resection rate</measure>
    <time_frame>up to 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR rate</measure>
    <time_frame>up to 10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Esophageal</condition>
  <arm_group>
    <arm_group_label>Endostar combined with MPFC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy regimens (er degree + mPFC) :&#xD;
Endostar:&#xD;
degrees 30 mg civ24h d0-6;&#xD;
Liposo:&#xD;
135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2&#xD;
Gimeracil and Oteracil Potassium (Tegafur):&#xD;
(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Endostar&quot;</intervention_name>
    <description>30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.</description>
    <arm_group_label>Endostar combined with MPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposo</intervention_name>
    <description>135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.</description>
    <arm_group_label>Endostar combined with MPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.</description>
    <arm_group_label>Endostar combined with MPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimeracil and Oteracil Potassium （Tegafur）</intervention_name>
    <description>40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.</description>
    <arm_group_label>Endostar combined with MPFC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with esophageal cancer confirmed by histology or cytology;&#xD;
&#xD;
          -  according to TNM staging for Ⅲ period, previous untreated can be removed and&#xD;
             potentially resectable esophageal cancer patients;&#xD;
&#xD;
          -  can eat more than liquid diet;No signs before esophageal perforation;No distant&#xD;
             metastasis;&#xD;
&#xD;
          -  male or female, age 18 and 75 years old or less or more;&#xD;
&#xD;
          -  ECOG PS 0 ~ 1 minute;&#xD;
&#xD;
          -  is expected to survive period for 3 months or more,&#xD;
&#xD;
          -  enough blood function: absolute neutrophil count (ANC) or 2 x 109 / L and the •&#xD;
             platelet count 100 x 109 / L or higher acuity 9 g/dL and hemoglobin;Liver function&#xD;
&#xD;
          -  enough: upper limit of total bilirubin acuities were normal (ULN);AST and ALT acuities&#xD;
             were 2.5 times the upper limit of normal (ULN);Alkaline phosphatase 5 times the upper&#xD;
             limit of normal or less (ULN);&#xD;
&#xD;
          -  enough renal function, serum creatinine or less normal limit (ULN) or calculated&#xD;
             creatinine clearance or 60 mL/min.&#xD;
&#xD;
          -  basic normal ecg, no healing trauma;&#xD;
&#xD;
          -  always not received anti-tumor drug treatment;&#xD;
&#xD;
          -  ever had had surgery patients, request to study treatment began to have more than 4&#xD;
             weeks, and the patient has recovered;&#xD;
&#xD;
          -  a complete uterus of female in the group within 28 days before the study must have a&#xD;
             negative pregnancy test results (except amenorrhea has 24 months).If the pregnancy&#xD;
             test from the first time for more than 7 days, is the need for urine pregnancy test&#xD;
             validation (within 7 days before the first delivery).&#xD;
&#xD;
          -  prior to biological agents, especially e. coli genetically engineered products without&#xD;
             severe allergic reactions;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  there is a clear taxol allergy history;&#xD;
&#xD;
          -  pregnancy, nursing mothers, or have fertility but not women using contraception;&#xD;
&#xD;
          -  the existing serious acute infection, and not be controlled;Or fester sex and chronic&#xD;
             infection, wound in delay no more;&#xD;
&#xD;
          -  the original serious heart disease, including: higher risk of congestive heart&#xD;
             failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe&#xD;
             valvular heart disease, and resistant hypertension;&#xD;
&#xD;
          -  is not easy to control nerve, mental illness or mental disorders, compliance is poor,&#xD;
             can't cooperate with accounts and response to treatment;Primary brain tumors or CNS&#xD;
             metastases illness did not get a control, has obvious symptoms in cranial hypertension&#xD;
             or nerve spirit;&#xD;
&#xD;
          -  with bleeding tendency;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gu Yanhong, PI</last_name>
    <role>Study Chair</role>
    <affiliation>China:Jiangsu people's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant human endostatin，Endo</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

